- Home
- CEV vs ADAP Comparison
CEV vs ADAP Comparison
Compare CEV & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- ADAP
- Stock Information
- Founded
- CEV 1999
- ADAP 2008
- Country
- CEV United States
- ADAP United Kingdom
- Employees
- CEV N/A
- ADAP N/A
- Industry
- CEV Finance/Investors Services
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- ADAP Health Care
- Exchange
- CEV Nasdaq
- ADAP Nasdaq
- Market Cap
- CEV 67.8M
- ADAP 75.5M
- IPO Year
- CEV N/A
- ADAP 2015
- Fundamental
- Price
- CEV $9.48
- ADAP $0.08
- Analyst Decision
- CEV
- ADAP Hold
- Analyst Count
- CEV 0
- ADAP 6
- Target Price
- CEV N/A
- ADAP $1.02
- AVG Volume (30 Days)
- CEV 19.6K
- ADAP 18.4M
- Earning Date
- CEV 01-01-0001
- ADAP 08-11-2025
- Dividend Yield
- CEV 4.23%
- ADAP N/A
- EPS Growth
- CEV N/A
- ADAP N/A
- EPS
- CEV 0.36
- ADAP N/A
- Revenue
- CEV N/A
- ADAP $179,639,000.00
- Revenue This Year
- CEV N/A
- ADAP N/A
- Revenue Next Year
- CEV N/A
- ADAP $38.72
- P/E Ratio
- CEV $29.36
- ADAP N/A
- Revenue Growth
- CEV N/A
- ADAP 878.53
- 52 Week Low
- CEV $8.83
- ADAP $0.08
- 52 Week High
- CEV $10.91
- ADAP $1.36
- Technical
- Relative Strength Index (RSI)
- CEV 42.56
- ADAP 25.83
- Support Level
- CEV $9.35
- ADAP $0.08
- Resistance Level
- CEV $9.61
- ADAP $0.36
- Average True Range (ATR)
- CEV 0.06
- ADAP 0.02
- MACD
- CEV -0.01
- ADAP -0.02
- Stochastic Oscillator
- CEV 38.24
- ADAP 1.38
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.